A
RCUS
Arcus Bioscience
18.99
-0.49-2.52%After Hours: 18.43 -0.56 -2.95%18:09 02/20 EST
OPEN/PREV CLOSE19.19/19.48
TODAY RANGE18.94-19.61
VOL1.15M
MARKET CAP2.31B
52 WEEK RANGE6.50-26.40
AVG VOL (3M)1.60M
% TURNOVER0.95%
TURNOVER--
P/E (TTM)-5.5332
% RANGE3.41%
EPS(TTM)-3.4320
P/E(FORWARD)-5.3644
P/B4.665
BVPS4.071
DIVIDEND--
P/S6.79
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.60B
SHARES OUTSTANDING121.67M
NEXT EARNINGS02/23-02/27
FREE FLOAT84.37M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·5d ago
Does Wells Fargo’s RCUS Downgrade Reveal Deeper Questions About Arcus Biosciences’ Casdatifan Strategy?
Simply Wall St·02/13 05:25
A Look At Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness
NASDAQ·02/12 20:16
Notable Thursday Option Activity: FSLY, GEO, RCUS
Benzinga·02/12 14:21
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Benzinga·02/12 14:00
What Analysts Are Saying About Arcus Biosciences Stock
Dow Jones·02/12 13:52
Arcus Biosciences Price Target Cut to $23.00/Share From $30.00 by Wells Fargo
Dow Jones·02/12 13:52
Arcus Biosciences Cut to Equal-Weight From Overweight by Wells Fargo
TipRanks·02/12 10:35
Wells Fargo downgrades Arcus Biosciences (RCUS) to a Hold
TipRanks·02/12 10:20
Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo
TipRanks·02/11 16:31
Arcus Advances Quemliclustat With New Phase 1 Study: What Investors Should Know
NASDAQ·02/05 12:58
Rapid Innovation is Reshaping Oncology: Stocks in Focus
Simply Wall St·01/17 00:33
Arcus’ 2026 Oncology Readouts And Phase 3 Progress Might Change The Case For Investing In RCUS
Dow Jones·01/13 17:35
Arcus Biosciences Price Target Raised to $28.00/Share From $16.00 by Goldman Sachs
Same Industry
Name/Symbol
Change%
Price